🇺🇸 FDA
Patent

US 7776607

Mammalian selenoprotein differentially expressed in tumor cells

granted A61KA61K38/00

Quick answer

US patent 7776607 (Mammalian selenoprotein differentially expressed in tumor cells) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Aug 12 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Aug 17 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 12 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K38/00